Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.

Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
Original Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical Research
Primary Examiner: David Guzo
Attorneys: David L. Berstein, Matthew P. Vincent, Ropes & Gray
Current U.S. Classification: 514/44.00R; 435/6.13; 435/325; 435/366; 435/370; 435/372; 435/372.2; 435/372.3; 435/455
International Classification: A61K/31711; C12N/510; C12N/1510

View patent at USPTO
Search USPTO Assignment Database

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US6528482Dec 17, 1999Mar 4, 2003Immunex CorporationReceptor activator of NF-
US6537763May 31, 2001Mar 25, 2003Immunex CorporationReceptor activator of NF-
US6545027Jun 7, 1995Apr 8, 2003Eli Lilly and CompanyMethods of modulating NF-kB transcription factor
US6562948May 30, 2001May 13, 2003Immunex CorporationReceptor activator of NF-
US6566553Aug 10, 2001May 20, 2003Millennium Pharmaceuticals, Inc.Synthesis of clasto-lactacystin
US6649164Jun 8, 2001Nov 18, 2003Immunex CorporationMethod for enhancing the functional capacity of dendritic cells
US6660268Mar 18, 1994Dec 9, 2003The President and Fellows of Harvard CollegeProteasome regulation of NF-KB activity
US6696453May 17, 2002Feb 24, 2004Alcon, Inc.Use of NF-
US6696498May 10, 2002Feb 24, 2004Consiglio Nazionale Della Richerche2-cyclopenten-1-one and its derivatives as inhibitors of the NF-kB factor
US6831057Oct 28, 1997Dec 14, 2004The University of North Carolina at Chapel HillUse of NF-
US6878735Jan 17, 2003Apr 12, 2005Board of Trustees of Michigan State UniversityMulti-substituted imidazolines and method of use thereof
US6884598Sep 20, 2001Apr 26, 2005Immunex CorporationScreening assays for agonists and antagonists of receptor activator of NF-κB
US6890909Jul 3, 1998May 10, 2005Fujisawa Pharmaceutical Co., Ltd.Brain-protective agent
US6890946Jun 21, 2002May 10, 2005Indiana University Research and Technology CorporationUse of parthenolide to inhibit cancer
US7081343Jun 18, 2001Jul 25, 2006The Regents of the University of CaliforniaMethods for identifying modulators of NF-KB activity
US7097834Dec 14, 1998Aug 29, 2006Amgen Inc.Osteoprotegerin binding proteins
US7186503Sep 19, 2003Mar 6, 2007Signal Pharmaceuticals LLCCompounds and methods for modulating activation of NF-κB
US7262274Apr 1, 2003Aug 28, 2007Immunex CorporationKits containing rank polypeptides
US7285654Jan 8, 2003Oct 23, 2007Signal PharmaceuticalsStimulus-inducible protein kinase complex and methods of use therefor
US7314936Jan 7, 2003Jan 1, 2008Eisai Co., Ltd.Deazapurines and uses thereof
US7364736Jun 25, 2002Apr 29, 2008Amgen Inc.
Amgen Fremont Inc.		Antibodies to OPGL
US7371411Dec 27, 2006May 13, 2008Novelos Therapeutics, Inc.Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US7411050Mar 16, 2004Aug 12, 2008Immunex CorporationMonoclonal blocking antibody to human RANKL
US7414120Jan 25, 2007Aug 19, 2008Signal PharmaceuticalsCompounds and methods for modulating activation of NF-κB
US7528161Dec 3, 2003May 5, 2009Michigan State UniversityNF-kappaB inhibitors and uses thereof
US7572594Apr 4, 2005Aug 11, 2009Immunex CorporationScreening assays for agonists or antagonists or receptor activator of NF-κB
US7585848Jan 11, 2005Sep 8, 2009Rush University Medical Center
Anges MG, Inc.		Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US7612114Jun 22, 2005Nov 3, 2009Eisai R&D Management Co., Ltd.Selective estrogen receptor modulator
US7628989Jun 17, 2005Dec 8, 2009Agensys, Inc.Methods of inducing an immune response
US7641905Jun 15, 2005Jan 5, 2010Agensys, Inc.Methods of inducing an immune response
US7652056Apr 6, 2005Jan 26, 2010Board of Trustees of Michigan State UniversityMulti-substituted imidazolines and method of use thereof
US7700073Sep 27, 2006Apr 20, 2010The University of North Carolina at Chapel HillUse of NF-κB inhibition in combination therapy for cancer
US7700543Nov 2, 2004Apr 20, 2010The University of North Carolina at Chapel HillUse NF-κB inhibition in combination therapy for cancer
US7700545Sep 27, 2006Apr 20, 2010The University of North Carolina at Chapel HillUse of NF-κB inhibition in combination therapy for cancer
US7718776Apr 7, 2003May 18, 2010Amgen Inc.
Medarex, Inc.		Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7736654Apr 10, 2002Jun 15, 2010Agensys, Inc.Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7744886Jun 24, 2008Jun 29, 2010Immunex CorporationMethods for interfering with rank signaling
US7759476Oct 22, 2007Jul 20, 2010Signal PharmaceuticalsDouble-stranded RNAS directed to IKK-2
US7790684Jun 11, 2008Sep 7, 2010Immunex CorporationMethod of inhibiting osteoclast activity
US7807795Dec 14, 1998Oct 5, 2010Amgen Inc.Antibodies to osteoprotegerin binding proteins
US7868002Sep 28, 2007Jan 11, 2011Eisai R&D Management Co., Ltd.Deazapurines and uses thereof
US7871983Feb 14, 2003Jan 18, 2011Anges MG Inc.Remedy and preventive for diseases caused by NF-κB
US7875274Dec 13, 2006Jan 25, 2011The Board of Trustees of the Leland Stanford Junior UniversityProtein modulators of resistance to alkylating agents
US7915009Dec 22, 2000Mar 29, 2011The Mathilda and Terence Kennedy Institute of Rheumatology TrustActivation and inhibition of the immune system
US7923008Jan 19, 2006Apr 12, 2011Amgen Inc.Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein
US7927597Apr 30, 2004Apr 19, 2011Agensys, Inc.Methods to inhibit cell growth
US7932375Jul 30, 2007Apr 26, 2011Immunex CorporationKits for detecting rank nucleic acids
US7943591May 12, 2008May 17, 2011Adynxx, Inc.Gene expression and pain
US7951375Jun 17, 2005May 31, 2011Agensys, Inc.Methods of inducing an immune response
US7960412Aug 20, 2009Jun 14, 2011Eisai R&D Management Co., Ltd.Selective estrogen receptor modulator
US8093225Mar 15, 2011Jan 10, 2012Adynxx, Inc.Gene expression and pain
US8153775Apr 22, 2011Apr 10, 2012Immunex CorporationKits for detecting rank

Claims

1. A method for inhibiting expression, in a eukaryotic cell, of a gene whose transcription is regulated by NF-KB, the method comprising reducing NF-KB activity in the cell such that expression of said gene is inhibited.

2. A method for selectively inhibiting expression, in a eukaryotic cell, of genes whose transcription is regulated by NF-B, the method comprising reducing NF-B activity in the cell such that expression of said genes is inhibited.

3. A method for reducing the level of expression of a viral gene whose transcription is regulated by NF-B in a eukaryotic cell, the method comprising reducing NF-B activity in the cell such that expression of said viral gene is reduced.

4. The method of claim 3, wherein the viral gene is a cytomegalovirus (CMV), human immunodeficiency virus (HIV) or simian virus 40 (SV40) gene.

5. A method for reducing the level of expression of a cytokine gene whose transcription is regulated by NF-B in a eukaryotic cell comprising reducing NF-B activity in the cell such that expression of said cytokine gene is reduced.

6. A method for diminishing induced NF-B-mediated intracellular signaling comprising reducing NF-B activity in cells such that NF-B-mediated intracellular signaling is diminished.

7. A method for modifying effects of external influences on a eukaryotic cell, which external influences induce NF-B-mediated intracellular signaling, the method comprising altering NF-B activity in the cells such that NF-B-mediated effects of external influences are modified.

8. The method of claim 7, wherein NF-B activity in the cell is reduced.

9. A method for reducing, in eukaryotic cells, the level of expression of genes which are activated by extracellular influences which induce NF-B-mediated intracellular signaling, the method comprising reducing NF-B activity in the cells such that expression of said genes is reduced.

10. A method for reducing the effects of bacterial infection on mammalian cells comprising reducing NF-B activity in mammalian cells so as to reduce bacterial lipopolysaccharide-induced gene expression in the mammalian cells.

11. A method for reducing the effects of viral infection on mammalian cells comprising reducing NF-B activity in mammalian cells so as to reduce virus-mediated gene expression in the mammalian cells.

12. A method for reducing the effects of bacterial infection on mammalian immune cells comprising reducing NF-B activity in mammalian immune cells so as to reduce bacterial lipopolysaccharide-mediated stimulation of the immune cells.

13. A method for reducing the effects of bacterial lipopolysaccharide on mammalian cells comprising reducing NF-B activity in the cells so as to reduce bacterial lipopolysaccharide-induced gene expression in the cells.

14. A method for reducing bacterial lipopolysaccharide-induced expression of cytokines in mammalian cells, which method comprises reducing NF-B activity in the cells so as to reduce bacterial lipopolysaccharide-induced expression of said cytokines in the cells.

15. A method for reducing bacterial lipopolysaccharide-induced expression of Tumor Necrosis Factor- in mammalian cells, which method comprises reducing NF-B activity in the cells so as to reduce bacterial lipopolysaccharide-induced expression of Tumor Necrosis Factor- in the cells.

16. A method for reducing bacterial lipopolysaccharide-mediated stimulation of immune cells, which method comprises reducing NF-B activity in the cells so as to reduce bacterial lipopolysaccharide-mediated stimulation of the immune cells.

17. A method for reducing bacterial-induced NF-B signaling in cells, which method comprises reducing NF-B activity in the cells so as to reduce bacterial-induced NF-B signaling in the cells.

18. A method for reducing Interleukin-1 or Tumor Necrosis Factor- activity in mammalian cells comprising reducing NF-B activity in the cells so as to reduce intracellular signaling caused by Interleukin-1 or Tumor Necrosis Factor- in the cells.

19. A method for reducing bacterial lipopolysaccharide-induced nuclear translocation of NF-B in eukaryotic cells comprising inhibiting one or more of: (a) modification of an IB protein which reduces binding to NF-B, (b) degradation of an IB protein, or (c) dissociation of NF-B-IB complexes so as to reduce nuclear translocation of NF-B in the cells.

20. The method of claim 1 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

21. The method of claim 1 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

22. The method of claim 1, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

23. The method of claim 1, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

24. The method of claim 1, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

25. The method of claim 1 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

26. The method of claim 1, carried out on mammalian cells.

27. The method of claim 1, carried out on human cells.

28. The method of claim 26 or 27, carried out on immune cells.

29. The-method of claim 26 or 27 carried out on lymphoid cells.

30. The method of claim 26 or 27, carried out on liver cells.

31. The method of claim 2 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

32. The method of claim 2 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

33. The method of claim 2, wherein NF-B activity is reduced by inhibiting modification of an I-B protein, which modification otherwise reduces IB binding to NF-B.

34. The method of claim 2, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

35. The method of claim 2, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

36. The method of claim 2 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

37. The method of claim 2, carried out on mammalian cells.

38. The method of claim 2, carried out on human cells.

39. The method of claim 37 or 38, carried out on immune cells.

40. The method of claim 37 or 38, carried out on lymphoid cells.

41. The method of claim 37 or 38, carried out on liver cells.

42. The method of claim 3 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

43. The method of claim 3 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

44. The method of claim 3, wherein NF-B activity is reduced by inhibiting modification of an I-B protein, which modification otherwise reduces IB binding to NF-B.

45. The method of claim 3, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

46. The method of claim 3, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

47. The method of claim 3 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

48. The method of claim 3, carried out on mammalian cells.

49. The method of claim 3, carried out on human cells.

50. The method of claim 48 or 49, carried out on immune cells.

51. The method of claim 48 or 49, carried out on lymphoid cells.

52. The method of claim 48 or 49, carried out on liver cells.

53. The method of claim 5 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

54. The method of claim 5 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

55. The method of claim 5, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

56. The method of claim 5, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

57. The method of claim 5, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

58. The method of claim 5 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

59. The method of claim 5, carried out on mammalian cells.

60. The method of claim 5, carried out on human cells.

61. The method of claim 59 or 60, carried out on immune cells.

62. The method of claim 59 or 60, carried out on lymphoid cells.

63. The method of claim 59 or 60, carried out on liver cells.

64. The method of claim 6 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

65. The method of claim 6 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

66. The method of claim 6, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

67. The method of claim 6, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

68. The method of claim 6, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

69. The method of claim 6 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

70. The method of claim 6, carried out on mammalian cells.

71. The method of claim 6, carried out on human cells.

72. The method of claim 70 or 71, carried out on immune cells.

73. The method of claim 70 or 71, carried out on lymphoid cells.

74. The method of claim 70 or 71, carried out on liver cells.

75. The method of claim 8 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

76. The method of claim 8 wherein NF-KB activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

77. The method of claim 8, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

78. The method of claim 8, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

79. The method of claim 8, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

80. The method of claim 8 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

81. The method of claim 7, carried out on mammalian cells.

82. The method of claim 8, carried out on mammalian cells.

83. The method of claim 7, carried out on human cells.

84. The method of claim 8, carried out on human cells.

85. The method of any of claims 81-84, carried out on immune cells.

86. The method of any of claims 81-84, carried out on lymphoid cells.

87. The method of any of claims 81-84, carried out on liver cells.

88. The method of claim 9 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

89. The method of claim 9 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

90. The method of claim 9, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

91. The method of claim 9, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

92. The method of claim 9, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

93. The method of claim 9 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

94. The method of claim 9, carried out on mammalian cells.

95. The method of claim 9, carried out on human cells.

96. The method of claim 94 or 95, carried out on immune cells.

97. The method of claim 94 or 95, carried out on lymphoid cells.

98. The method of claim 94 or 95, carried out on liver cells.

99. The method of claim 10 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

100. The method of claim 10 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

101. The method of claim 10, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

102. The method of claim 10, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

103. The method of claim 10, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

104. The method of claim 10 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

105. The method of claim 10, carried out on human cells.

106. The method of claim 11, carried out on immune cells.

107. The method of claim 11, carried out on lymphoid cells.

108. The method of claim 11, carried out on liver cells.

109. The method of claim 11 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

110. The method of claim 11 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

111. The method of claim 11, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

112. The method of claim 11, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

113. The method of claim 11, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

114. The method of claim 11 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

115. The method of claim 11, carried out on human cells.

116. The method of claim 11 or 115, carried out on immune cells.

117. The method of claim 11 or 115, carried out on lymphoid cells.

118. The method of claim 11 or 115, carried out on liver cells.

119. The method of claim 12 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

120. The method of claim 12 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

121. The method of claim 12, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

122. The method of claim 12, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

123. The method of claim 12, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

124. The method of claim 12 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

125. The method of claim 12, carried out on human immune cells.

126. The method of claim 12, carried out on lymphoid cells.

127. The method of claim 125, carried out on lymphoid cells.

128. The method of claim 13 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

129. The method of claim 13 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

130. The method of claim 13, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

131. the method of claim 13, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

132. The method of claim 13, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

133. The method of claim 13 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

134. The method of claim 13, carried out on human cells.

135. The method of claim 13, carried out on immune cells.

136. The method of claim 134, carried out on immune cells.

137. The method of claim 13 or 134, carried out on lymphoid cells.

138. The method of claim 13 or 134, carried out on liver cells.

139. The method of claim 14 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

140. The method of claim 14 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

141. The method of claim 14, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

142. The method of claim 14, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

143. The method of claim 14, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

144. The method of claim 14 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

145. The method of claim 14, carried out on human cells.

146. The method of claim 14 or 145, carried out on immune cells.

147. The method of claim 14 or 145, carried out on lymphoid cells.

148. The method of claim 14 or 145, carried out on liver cells.

149. The method of claim 15 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

150. The method of claim 15 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

151. The method of claim 15, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

152. The method of claim 15, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

153. The method of claim 15, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

154. The method of claim 15 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

155. The method of claim 15, carried out on human cells.

156. The method of claim 15 of 155, carried out on immune cells.

157. The method of claim 15 or 155, carried out on lymphoid cells.

158. The method of claim 15 or 155, carried out on liver cells.

159. The method of claim 16 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

160. The method of claim 16 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

161. The method of claim 16, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

162. The method of claim 16, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

163. The method of claim 16, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

164. The method of claim 16 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

165. The method of claim 16, carried out on human cells.

166. The method of claim 16 or 165, carried out on lymphoid cells.

167. The method of claim 17 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

168. The method of claim 17 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

169. The method of claim 17, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

170. The method of claim 17, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

171. The method of claim 17, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

172. The method of claim 17 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

173. The method of claim 17, carried out on human cells.

174. The method of claim 17 or 173, carried out on immune cells.

175. The method of claim 17 or 173, carried out on lymphoid cells.

176. The method of claim 17 or 173, carried out on liver cells.

177. The method of claim 18 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

178. The method of claim 18 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

179. The method of claim 18, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

180. The method of claim 18, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

181. The method of claim 18, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

182. The method of claim 18 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

183. The method of claim 18, carried out on human cells.

184. The method of claim 18 or 183, carried out on immune cells.

185. The method of claim 18 or 183, carried out on lymphoid cells.

186. The method of claim 18 or 183, carried out on liver cells.

187. The method of claim 19, carried out on mammalian cells.

188. The method of claim 19, carried out on human cells.

189. The method of claim 187 or 188, carried out on immune cells.

190. The method of claim 187 or 188, carried out on lymphoid cells.

191. The method of claim 193 or 194, carried out on liver cells.

192. The method of claim 4 wherein NF-B activity is reduced by decreasing the level of NF-B not bound in an NF-B:IB complex.

193. The method of claim 4 wherein NF-B activity is reduced by inhibiting the passage of NF-B into the nucleus of cells.

194. The method of claim 4, wherein NF-B activity is reduced by inhibiting modification of an IB protein, which modification otherwise reduces IB binding to NF-B.

195. The method of claim 4, wherein NF-B activity is reduced by inhibiting degradation of an IB protein.

196. The method of claim 4, wherein NF-B activity is reduced by inhibiting dissociation of NF-B:IB complexes.

197. The method of claim 4 wherein reducing NF-B activity comprises reducing binding of NF-B to NF-B recognition sites on genes which are transcriptionally regulated by NF-B.

198. The method of claim 4, carried out on mammalian cells.

199. The method of claim 4, carried out on human cells.

200. The method of claim 198 or 199, carried out on immune cells.

201. The method of claim 198 or 199, carried out on lymphoid cells.

202. The method of claim 198 or 199, carried out on liver cells.

203. A method of inhibiting expression, in a mammalian cell, of a gene whose transcriptional activity is activated by binding of NF-B to said gene, comprising introducing a nucleic acid decoy molecule into the cell in an amount sufficient to inhibit expression of the gene, which decoy includes a NF-B binding site that binds to NF-B.

Drawings